Diamyd Medical elected to present Diamyd® meta-analysis results at the EASD diabetes conference
A scientific abstract detailing the latest findings from a meta-analysis based on data from more than 600 individuals with type 1 diabetes that have participated in clinical trials with the diabetes vaccine Diamyd® (GAD-alum) has been elected to be presented orally the 57th EASD Annual Meeting (European Association for the Study of Diabetes).
The abstract which summarizes the results from the meta-analysis is titled “The influence of HLA haplotype, number of injections and administration route on the effect of GAD-specific immunotherapy in type 1 diabetes" and will be presented live by Ulf Hannelius, CEO of Diamyd Medical. The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2, representing approximately half of all type 1 diabetes patients.
The conference will be held virtually from 27 September - 1 October 2021. The session where the presentation is given, “OP 43 Genes, epigenes and telomeres in type 1 diabetes”, will take place on Friday Oct 1, 2021, 12:30 - 1:30 PM; please note that the indicated times are CEST. The abstract will be published on the EASD:s website and in the online version of Diabetologia.
For more information on the 57th EASD Annual Meeting see https://www.easd.org/annual-meeting/easd-2021.html
The European Association for the Study of Diabetes e.V. (EASD) is a non-profit, medical scientific association. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. Preparations for a confirmatory Phase III trial in the US and Europe are on-going, to start recruting patients later in 2021. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: email@example.com.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: firstname.lastname@example.org Reg. no.: 556242-3797 Website: https://www.diamyd.com
The information was submitted for publication, through the agency of the contact person set out above, at 14.15 CET on June 2, 2021.